← Back to Screener
Turn Therapeutics Inc. Common Stock (TTRX)
Price$3.42
Favorite Metrics
Price vs S&P 500 (26W)-54.99%
Price vs S&P 500 (4W)-7.26%
Market Capitalization$102.17M
All Metrics
Book Value / Share (Quarterly)$0.02
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-15.59%
10-Day Avg Trading Volume0.04M
EPS (Annual)$-0.06
ROI (Annual)-2672.58%
Cash / Share (Quarterly)$0.11
ROA (Last FY)-86.31%
Cash Flow / Share (Annual)$-0.05
P/B Ratio202.72x
P/B Ratio (Quarterly)389.19x
Net Interest Coverage (TTM)-49.20x
EPS Incl Extra (Annual)$-0.06
Current Ratio (Annual)1.55x
Quick Ratio (Quarterly)1.35x
3-Month Avg Trading Volume0.04M
52-Week High$26.50
EPS Excl Extra (Annual)$-0.06
26-Week Price Return-51.00%
Quick Ratio (Annual)1.23x
13-Week Price Return-18.91%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.43x
Enterprise Value$99.067
Cash / Share (Annual)$0.03
3-Month Return Std Dev66.77%
ROE (Last FY)-2672.58%
EPS Basic Excl Extra (Annual)$-0.06
Total Debt / Equity (Quarterly)0.00x
Revenue / Share (Annual)$0.00
Year-to-Date Return-12.94%
5-Day Price Return-2.28%
EPS Normalized (Annual)$-0.06
Month-to-Date Return7.19%
EBITD / Share (Annual)$-0.06
Price vs S&P 500 (13W)-19.60%
Beta-0.34x
52-Week Low$2.57
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TTRXTurn Therapeutics Inc. Common Stock | — | — | — | — | $3.42 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Turn Therapeutics is a clinical-stage biotechnology company developing treatments for dermatology, wound care, and infectious diseases. The company's proprietary PermaFusion platform enhances drug stability and bioavailability, enabling lower doses and reduced side effects. Its lead programs target moderate to severe eczema and onychomycosis.